Learning from the thymic human cell atlas for T cell engineering

Lead Research Organisation: Wellcome Sanger Institute
Department Name: Cellular Genetics

Abstract

One of the central questions in immunology is how adaptive immunity generates its diversity while maintaining tolerance. The key
mediators of tolerance are T cells, which develop in the thymus, where thymocytes rearrange their T cell receptor genes and undergo
positive and negative selection. This ensures their ability to recognise antigen in the context of MHC, whilst avoiding self-reactivity.
We are still far from fully understanding the steps in these processes at the molecular level, especially in humans: What are the
developmental trajectories of different T cell subtypes, and how do they relate to their journey through the organ during maturation?
What is the functional role played by the macro- and micro-scale environments in regulating this? These questions have gained in
importance since several T cell types are now therapeutics in cancer and transplantation, raising the question of how to engineer
specific T cell subsets in vitro.
In AIM 1, we propose to generate an organ-scale 3D thymic cell atlas at full genomic breadth through genomics and imaging
technologies. By combining multi-modal single cell genomics with multi-scale spatial genomics and imaging technologies, we will
generate a rich data set for deep and comprehensive reconstruction of tissue architectures in a thymic lobe.
In AIM 2, we will carry out computational data integration with new methods for 3D multi-modal atlas assembly to predict
lymphocyte developmental mechanisms at micro and macro scales.
In AIM 3, we will use an artificial thymic organoid system to simultaneously validate our findings and enhance T cell engineering
approaches.
This powerful integrated approach combines genomics, imaging and tissue engineering together with computational analyses to
dissect design principles of the thymus, a central organ of the immune system. This knowledge will guide the development of
engineered T cells as research reagents, and ultimately as therapeutics.

Publications

10 25 50